COVID-19 vaccine hesitancy in patients with systemic autoimmune rheumatic disease: an interview-based survey.
COVID-19 vaccine hesitancy in patients with systemic autoimmune rheumatic disease: an interview-based survey.
复制标题
DOI：
10.1007/s00296-021-04938-9
复制
发表时间：
2021-09
影响因子：
4
通讯作者：
Shukla A
中科院分区：
文献类型：
--
作者：
Gaur P;Agrawat H;Shukla A
患有全身性自身免疫性风湿病（AIRD）的患者易受SARS Cov-2感染。针对这种感染的疫苗可以防止患者发展为严重的疾病。但这一群体对疫苗的犹豫不决可能成为一个障碍。因此，有必要了解AIRD患者对疫苗接种的看法。该研究是一项基于访谈的调查，在AIRD患者和普通人群的对照组中进行。问卷包括受试者的人口统计学详细信息、持续时间、诊断、AIRD活动以及关于疫苗接种感知的问题。该调查包括280名AIRD患者和102名对照组。54%（152/280）的患者和67%（68/102）的对照愿意接种疫苗（p = 0.03）。年龄> 45岁的患者比年龄≤ 45岁的患者更愿意接种疫苗（61.9%对44.8%; p = 0.001）。文化程度低的患者比毕业及以上的患者对疫苗接种有更多的犹豫（38%对69%; p < 0.001）。对疫苗犹豫不决的常见原因是尚未决定，与疫苗副作用有关的恐惧和疾病恶化。29%（82/280）的患者已接种疫苗，其中35%（35/82）发生轻度事件（发热/肌痛/头痛）。AIRD患者的副作用比对照组少，仅在1例患者中观察到疾病发作。因此，教育AIRD患者接种疫苗的利弊，特别是关于免疫性疾病，可以帮助我们克服疫苗犹豫。信息应该清楚地渗透到，COVID-19免疫接种的AIRD耀斑风险可以忽略不计，副作用轻微且可控。
Patients with a systemic autoimmune rheumatic disease (AIRD) are vulnerable to SARS Cov-2 infection. Vaccination against this infection can prevent the patients from developing severe disease. But vaccine hesitancy in this group can emerge as a hurdle. So there is a need to understand the perception regarding vaccination in AIRD patients. The study is an interview-based survey done in AIRD patients and a control group from the general population. The questionnaire included the subject’s demographic details, duration, diagnosis, the activity of AIRD, and questions regarding the perception of the vaccination. The survey included 280 patients with AIRD and 102 control subjects. 54% (152/280) of the patients and 67% (68/102) of the controls were willing to get vaccinated (p = 0.03). Patients > 45-years of age were more willing to vaccinate than those with age ≤ 45-years (61.9% vs. 44.8%; p = 0.001). Patients with lower education had more vaccine hesitancy than those with graduation and above (38% vs. 69%; p < 0.001). The common reason for vaccine hesitancy was not-yet-decided, fear related to vaccine side-effects, and disease worsening. 29% (82/280) patients were already vaccinated, out of which 35% (35/82) had mild events (fever/myalgia/headache). AIRD patients had fewer side effects than controls, and disease flare was seen in only one patient. Thus, educating AIRD patients regarding the pros and cons of vaccination, particularly concerning immunological disease, can help us overcome vaccine hesitancy. The message should clearly penetrate that there is a negligible risk of AIRD-flares with the COVID-19 immunization and the side effects are mild and manageable.
登录
查看更多内容
影响因子：
4.5
作者：
Gaur PS;Zimba O;Agarwal V;Gupta L
通讯作者：
Gupta L
影响因子：
5.2
作者：
Troiano G;Nardi A
通讯作者：
Nardi A
影响因子：
13.6
作者：
Xu C;Yi Z;Cai R;Chen R;Thong BY;Mu R
通讯作者：
Mu R
DOI：
10.1016/s2665-9913(21)00039-4
发表时间：
2021-04
期刊：
The Lancet. Rheumatology
影响因子：
--
作者：
Felten R;Dubois M;Ugarte-Gil MF;Chaudier A;Kawka L;Bergier H;Costecalde C;Pijnenburg L;Fort J;Chatelus E;Sordet C;Javier RM;Gottenberg JE;Sibilia J;Fuentes-Silva Y;Arnaud L
通讯作者：
Arnaud L
影响因子：
25.4
作者：
Zhong, Jixin;Shen, Guifen;Dong, Lingli
通讯作者：
Dong, Lingli